The Indian Supreme Court’s rejection of Novartis’s Glivec patent brought the increasingly tense debate about the balance between patent rights and access to medicines to the forefront. Anand Grover, who successfully represented the Cancer Patient Aid Association in the case, argues that the patent system may not be the best way to encourage drug research
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Law firms that pay close attention to their client relationships are more likely to win repeat work, according to a survey of nearly 29,000 in-house counsel
Saya Choudhary of Singh & Singh explains how her team navigated nine years of litigation to secure record damages of $29 million and the lessons learned along the way
The Irish government has delayed a planned referendum on whether Ireland should join the Unified Patent Court, prompting concern about when a vote may take place